Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (27.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 27.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | s exhibit 10.1 to this current report on Form 8-K.Item 5.02 Departure of Directors or Certain Officers; Election of Dire |
| 22.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 06.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | y set forth by specific reference in such filing. Item 5.02. Departure of Directors or Certain Officers; Election of Dir |
| 06.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 07.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
Stammdaten
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Unternehmen & Branche
| Name | MBX Biosciences, Inc. |
|---|---|
| Ticker | MBX |
| CIK | 0001776111 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 937,2 Mio. USD |
| Beta | 1,25 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -86,971,000 | -2.38 | 385,144,000 | 369,223,000 | |
| 2025-09-30 | 10-Q | -21,618,000 | -0.63 | 400,076,000 | 387,538,000 | |
| 2025-06-30 | 10-Q | -19,411,000 | -0.58 | 231,522,000 | 219,239,000 | |
| 2025-03-31 | 10-Q | -23,880,000 | -0.71 | 245,926,000 | 235,422,000 | |
| 2024-12-31 | 10-Q | -61,900,000 | 268,535,000 | 257,442,000 | ||
| 2024-12-31 | 10-K | -61,922,000 | -5.82 | 268,535,000 | 257,442,000 | |
| 2024-09-30 | 10-Q | -18,142,000 | -2.78 | 282,400,000 | 271,368,000 | |
| 2024-06-30 | 10-Q | -15,857,000 | -12.62 | -97,885,000 | ||
| 2024-03-31 | 10-Q | -12,337,000 | -10.26 | -83,047,000 | ||
| 2023-12-31 | 10-K | -32,563,000 | -31.96 | 84,180,000 | -72,468,000 | |
| 2023-12-31 | 10-Q | -32,600,000 | 84,180,000 | -72,468,000 | ||
| 2023-09-30 | 10-Q | -10,162,000 | -9.40 | -64,819,000 | ||
| 2023-06-30 | 10-Q | -7,608,000 | -55,390,000 | |||
| 2023-03-31 | 10-Q | -5,949,000 | -48,272,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-17 | Hoerter Steven L. | Director | Open Market Purchase | 20,000 | 13.25 | 264,984.00 | +4,3% | |
| 2025-09-26 | Heron Patrick J | Director, 10% Owner | Open Market Purchase | 666,666 | 18.00 | 11,999,988.00 | +195,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.